Indiplon Driving Study Could Push Marketing Into High Gear
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer/Neurocrine's insomnia drug – which just had its user fee date extended – would still have class warnings, but could enjoy a labeling advantage over competitors.